GENOMICA presents a new liquid biopsy test for the detection of mutations in lung cancer

- The diagnostic kit called CLART® CMA EGFR enables the detection of 40 high prevalence mutations of the EGFR gene, allowing for the selection of a more adequate treatment for patients with non-small cell lung cancer
- The presented data also confirms a sensitivity of 100% and a specificity of 96.5%

Madrid, September 11th, 2017.- Within the framework of the European Society for Medical Oncology (ESMO) Congress, GENOMICA, leader in the field of molecular diagnostics, and belonging to PharmaMar (MSE:PHM), has presented positive results for its CLART® CMA EGFR diagnostic kit, demonstrating a high specificity, sensibility and concordance with other diagnostic platforms for non-small cell lung cancer (NSCLC) for use in hospitals. The abstract titled “Clinical evaluation of low density array based EGFR mutation detecting kit using tissue samples and liquid biopsies” (abstract 1264P) confirms the reliability and validity as a diagnostic tool for the daily clinical routine for this type of tumor.

This innovative technique enables the detection and identification of 40 mutations of the epidermic growth factor receptor (EGFR), relevant in NSCLC from a DNA analysis both of tissue and in blood, through a liquid biopsy process.

The information obtained through this study of the mutations found in EGFR allows for the choice of the most adequate treatment for patients with NSCLC, also permitting a follow-up and detection of any resistance throughout the treatment. GENOMICA´s technology enables the identification through this kit, of mutations in sensibility and resistance in the 18, 19, 20 and 21 exons.

The samples of EGFR presented at ESMO Congress, analyzed through CLART® CMA EGFR showed a 96.3% concordance with the routine methods used in hospital practice, 107 biopsies were previously obtained from patients with metastatic NSCLC, these samples being analyzed at two Spanish university hospitals: Vall d'Hebron Hospital (Barcelona) and 12 de Octubre Hospital (Madrid).

These measures now form part of the standard protocols for the treatment of cancer.
Quicker and easier

The CLART® CMA EGFR-LB kit can be added to the rest of the CLART® CMA line, that covers the detection of mutations in oncogenes, associated not only to lung cancer but also to colorectal cancer and melanoma.

The detection technique comprises of three steps: the extraction and purification of tumoral DNA in blood; the amplification of the genetic material extracted by multiplex PCR, followed by the visualization on low-density micro-array platforms, where the interpretation and emission of results is totally automatic. This process, that is highly complex, is done in record time: GENOMICA’s technology enables the analysis of up to 95 samples automatically and in a maximum time of six hours. Also the use of this same semi-automated platform for tissue samples and liquid biopsies eases laboratory work and reduces turn over time per sample.

The Spanish multinational has opened up a path in the field of molecular diagnostics through its firm, GENOMICA, entirely focused on the development of complete solutions to the diagnosis of the genetic mutations involved in cancer.

About GENOMICA

GENOMICA is the first Spanish company in Molecular Diagnostics and highly experienced in the analysis of genetic identification. Founded in 1990, with facilities in Madrid, GENOMICA is 100% owned by PharmaMar. It is our mission to improve the present molecular diagnostics tools and the human identification methods through reliability, automation and the highest quality standards.

Our main objective is to maintain leadership in genomics applications within the Spanish market, and to internationally extend our activities in the area of Molecular Diagnostics by means of the design, development, automation, and commercialization of new diagnostic applications of our innovative technological platform, Clinical Arrays Technology, CLART®.

GENOMICA has developed diagnostic tests for human papillomavirus associated with cervical cancer, the diagnosis of viral respiratory diseases, multiple detection of human herpes and enteroviruses, as well as detection of gene regions associated to the determination of human therapy response factors, in particular in the Oncology field.

GENOMICA also provides analysis of DNA, Legal and Forensic Medicine, and Technology Transfer services. For more information http://www.genomica.es.
Disclaimer
This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:
Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215
Phone: +34 918466000

Investor Relations:
Phone: +34 914444500
Or please visit our website at www.pharmamar.com